NASDAQ:EOLS - Evolus Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$26.63 +2.78 (+11.66 %)
(As of 03/19/2019 04:00 PM ET)
Previous Close$23.85
Today's Range$24.00 - $27.94
52-Week Range$6.75 - $39.50
Volume130,022 shs
Average Volume899,984 shs
Market Capitalization$726.20 million
P/E Ratio-98.41
Dividend YieldN/A
BetaN/A
Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.

Receive EOLS News and Ratings via Email

Sign-up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EOLS
CUSIPN/A
Phone949-284-4555

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Net Income$-4,480,000.00

Miscellaneous

EmployeesN/A
Market Cap$726.20 million
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable

Evolus (NASDAQ:EOLS) Frequently Asked Questions

What is Evolus' stock symbol?

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

How were Evolus' earnings last quarter?

Evolus Inc (NASDAQ:EOLS) posted its quarterly earnings data on Monday, March, 18th. The company reported ($0.46) earnings per share for the quarter, beating analysts' consensus estimates of ($0.55) by $0.09. View Evolus' Earnings History.

When is Evolus' next earnings date?

Evolus is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Evolus.

What price target have analysts set for EOLS?

6 brokerages have issued twelve-month price targets for Evolus' shares. Their forecasts range from $27.00 to $37.00. On average, they expect Evolus' share price to reach $31.6667 in the next year. This suggests a possible upside of 19.2% from the stock's current price. View Analyst Price Targets for Evolus.

What is the consensus analysts' recommendation for Evolus?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evolus.

What are Wall Street analysts saying about Evolus stock?

Here are some recent quotes from research analysts about Evolus stock:
  • 1. According to Zacks Investment Research, "Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California. " (2/5/2019)
  • 2. Cantor Fitzgerald analysts commented, "Based on our due diligence, dermatologists and plastic surgeons appreciate the value proposition of Evolus’s botulinum toxin as a nearly identical product to market-leader Botox sold at a discount. Therefore, we think DWP-450 could pick up meaningful market share if it is approved. and other potential upcoming catalysts should drive EOLS shares higher. Valuation Summary We use a blend of EV/EBITDA and DCF analysis to arrive at our $35 12-month price target." (9/17/2018)

Has Evolus been receiving favorable news coverage?

Headlines about EOLS stock have trended neutral on Tuesday, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Evolus earned a news impact score of 0.4 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the immediate future.

Who are some of Evolus' key competitors?

What other stocks do shareholders of Evolus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolus investors own include Advanced Micro Devices (AMD), Vanda Pharmaceuticals (VNDA), Cronos Group (CRON), Netflix (NFLX), Alibaba Group (BABA), Micron Technology (MU), Celadon Group (CGI), NVIDIA (NVDA), Adobe (ADBE) and Zymeworks (ZYME).

Who are Evolus' key executives?

Evolus' management team includes the folowing people:
  • Dr. Rui Avelar M.D., Chief Medical Officer & Head of R&D (Age 57)
  • Mr. David Moatazedi, Pres ,CEO & Director (Age 41)
  • Ms. Lauren P. Silvernail, CFO & Exec. VP of Corp. Devel. (Age 60)
  • Mr. Alejandro Sabad, VP of Operations
  • Jeffrey J. Plumer, VP of Legal

When did Evolus IPO?

(EOLS) raised $65 million in an IPO on Thursday, February 8th 2018. The company issued 5,000,000 shares at a price of $12.00-$14.00 per share. Cantor and Mizuho Securities served as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

Who are Evolus' major shareholders?

Evolus' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.42%), Prosight Management LP (0.72%), Tygh Capital Management Inc. (0.65%), Advisor Group Inc. (0.47%), Geode Capital Management LLC (0.46%) and Geode Capital Management LLC (0.46%). Company insiders that own Evolus stock include Bosun Hau, Corp Alphaeon, David N Gill, Kristine Romine, Michael M Jafar and Vikram Malik. View Institutional Ownership Trends for Evolus.

Which major investors are selling Evolus stock?

EOLS stock was sold by a variety of institutional investors in the last quarter, including United Services Automobile Association, Barclays PLC and Squarepoint Ops LLC. View Insider Buying and Selling for Evolus.

Which major investors are buying Evolus stock?

EOLS stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Advisor Group Inc., Chartwell Investment Partners LLC, Prosight Management LP, Two Sigma Investments LP, Geode Capital Management LLC, Geode Capital Management LLC and Citigroup Inc.. Company insiders that have bought Evolus stock in the last two years include Bosun Hau, David N Gill, Kristine Romine, Michael M Jafar and Vikram Malik. View Insider Buying and Selling for Evolus.

How do I buy shares of Evolus?

Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Evolus' stock price today?

One share of EOLS stock can currently be purchased for approximately $26.57.

How big of a company is Evolus?

Evolus has a market capitalization of $724.56 million. The company earns $-4,480,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis.

What is Evolus' official website?

The official website for Evolus is http://www.evolus.com.

How can I contact Evolus?

Evolus' mailing address is 17901 Von Karman Avenue Suite 150, Irvine CA, 92614. The company can be reached via phone at 949-284-4555 or via email at [email protected]


MarketBeat Community Rating for Evolus (NASDAQ EOLS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  169 (Vote Outperform)
Underperform Votes:  147 (Vote Underperform)
Total Votes:  316
MarketBeat's community ratings are surveys of what our community members think about Evolus and other stocks. Vote "Outperform" if you believe EOLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EOLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/19/2019 by MarketBeat.com Staff

Featured Article: What are gap-up stocks?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel